日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A CD138+ tumor-associated macrophage/Siglec-F+ neutrophil feed-forward loop promotes immune evasion in pancreatic cancer

CD138+肿瘤相关巨噬细胞/Siglec-F+中性粒细胞前馈环路促进胰腺癌的免疫逃逸

Wang, Chao; Zhang, Qi; Huang, Jinyan; Lin, Fangyu; Zhao, Danyang; Mu, Youling; Tong, Junshuo; Li, Jinping; Liang, Yingjiqiong; Zeng, Tao; Shi, Fukang; Shen, Hang; Lu, Tingting; Liang, Tingbo

Diabetes exacerbates destructive inflammation by activating the CD137L-CD137 axis in dendritic and IL-17+ T cells

糖尿病通过激活树突状细胞和IL-17+ T细胞中的CD137L-CD137轴加剧破坏性炎症。

Huang, Xin; Liu, Min; Gonzalez, Michael V; Debnath, Rahul; Afzali, Hamideh; Choi, Yongwon; Kim, Su Ah; Ko, Kang I; Graves, Dana T

Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity

通过阻断LTβR选择性清除循环效应CD8 T细胞,可将抗CD137的疗效与毒性区分开来。

Shein, Sergey A; Korchagina, Anna A; Wang, Li-Ju; Lai, Zhao; Chen, Yidong; Fisher, Jacob S; Ludewig, Burkhard; Lancaster, Jessica N; Fu, Yang-Xin; Koroleva, Ekaterina; Tumanov, Alexei V

Dual-targeting CD133/PD-L1 CAR-T plus αPD-1 overcomes immunosuppressive microenvironment and enhanced by radiation pre-conditioning.

双靶向 CD133/PD-L1 CAR-T 加 αPD-1 可克服免疫抑制微环境,并可通过放射预处理增强疗效。

PFKP is required for chemoresistant phenotype of breast cancer through modulating the formation of CD133(+) cancer stem like cells

PFKP通过调节CD133(+)癌干细胞样细胞的形成,在乳腺癌的化疗耐药表型中发挥作用。

Fang, Kai; Ma, Yue; Li, Lihua; Yue, Yan; Ruan, Hang; Xiong, Sidong

CD13 is a bona-fide marker of bovine pre-adipocytes with potential in cultivated fat applications.

CD13 是牛前脂肪细胞的可靠标志物,在培养脂肪应用方面具有潜力。

Lee Seungmee, Thrower Thomas, Riley Susanna E, Esteves Cristina L, Donadeu F Xavier

Stemness and Survival: CD117(+)/CD133(+) Subpopulations Sustain PI3K Signaling and Drive Imatinib Resistance in Head and Neck Mucosal Melanoma

干细胞特性与存活:CD117(+)/CD133(+)亚群维持PI3K信号通路并驱动头颈部黏膜黑色素瘤的伊马替尼耐药性

Hassan, Sofie-Yasmin; Santourlidis, Simeon; Flanagan, Thomas W; Hassan, Sarah-Lilly; Zhou, He; Schmidt, Morna F; Cacchi, Claudio; Lammert, Matthias Ferdinand; Megahed, Mossad; Yazdi, Amir Sadegh; Jonigk, Danny David; Araúzo-Bravo, Marcos J; Brodell, Robert T; Facca, Sybille; Haikel, Youssef; Hassan, Mohamed

GPC3 and CD133-targeted peptide dual modification enhances the therapeutic effect of doxorubicin carried by OMVs on hepatocellular carcinoma.

GPC3 和 CD133 靶向肽双重修饰增强了 OMV 携带的阿霉素对肝细胞癌的治疗效果。

CD133/CD49a discriminate between human pluripotent stem cell-derived pancreatic beta and alpha cells

CD133/CD49a 可区分人多能干细胞来源的胰腺β细胞和α细胞。

Tian, Chenglei; Di, Yilin; Muhammad, Aisha; Semb, Henrik

Targeting intratumoral regulatory T cells by CD137 aptamer-shRNA chimeras

利用 CD137 适体-shRNA 嵌合体靶向肿瘤内调节性 T 细胞

Lee, Kang Yi; Mei, Yu; Liu, Haiyan; Schwarz, Herbert